5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients
- PMID: 30249462
- DOI: 10.1016/j.jacc.2018.08.2146
5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients
Abstract
Background: The CoreValve U.S. Pivotal High Risk Trial was the first randomized trial to show superior 1-year mortality of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among high operative mortality-risk patients.
Objectives: The authors sought to compare TAVR to SAVR for mid-term 5-year outcomes of safety, performance, and durability.
Methods: Surgical high-risk patients were randomized (1:1) to TAVR with the self-expanding bioprosthesis or SAVR. VARC-1 (Valve Academic Research Consortium I) definitions were applied. Severe hemodynamic structural valve deterioration was defined as a mean gradient ≥40 mm Hg or a change in gradient ≥20 mm Hg or new severe aortic regurgitation. Five-year follow-up was planned.
Results: A total of 797 patients were randomized at 45 U.S. centers, of whom 750 underwent an attempted implant (TAVR = 391, SAVR = 359). The overall mean age was 83 years, and the STS score was 7.4%. All-cause mortality rates at 5 years were 55.3% for TAVR and 55.4% for SAVR. Subgroup analysis showed no differences in mortality. Major stroke rates were 12.3% for TAVR and 13.2% for SAVR. Mean aortic valve gradients were 7.1 ± 3.6 mm Hg for TAVR and 10.9 ± 5.7 mm Hg for SAVR. No clinically significant valve thrombosis was observed. Freedom from severe SVD was 99.2% for TAVR and 98.3% for SAVR (p = 0.32), and freedom from valve reintervention was 97.0% for TAVR and 98.9% for SAVR (p = 0.04). A permanent pacemaker was implanted in 33.0% of TAVR and 19.8% of SAVR patients at 5 years.
Conclusions: This study shows similar mid-term survival and stroke rates in high-risk patients following TAVR or SAVR. Severe structural valve deterioration and valve reinterventions were uncommon. (Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement; NCT01240902).
Keywords: aortic valve stenosis; surgical valve replacement; transcatheter aortic valve implantation; transcatheter aortic valve replacement.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Surgical Versus First-Generation Self-Expanding Transcatheter Aortic Valve Replacement: Is TAVR More Durable?J Am Coll Cardiol. 2018 Dec 4;72(22):2697-2700. doi: 10.1016/j.jacc.2018.09.044. J Am Coll Cardiol. 2018. PMID: 30497555 No abstract available.
Similar articles
-
3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement.J Am Coll Cardiol. 2016 Jun 7;67(22):2565-74. doi: 10.1016/j.jacc.2016.03.506. Epub 2016 Apr 3. J Am Coll Cardiol. 2016. PMID: 27050187 Clinical Trial.
-
Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk.J Am Coll Cardiol. 2019 Feb 12;73(5):546-553. doi: 10.1016/j.jacc.2018.10.083. J Am Coll Cardiol. 2019. PMID: 30732707 Clinical Trial.
-
Self-Expanding Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Patients at High Risk for Surgery: A Study of Echocardiographic Change and Risk Prediction.Circ Cardiovasc Interv. 2016 Jun;9(6):e003426. doi: 10.1161/CIRCINTERVENTIONS.115.003426. Circ Cardiovasc Interv. 2016. PMID: 27313280 Clinical Trial.
-
Low-Risk Transcatheter Versus Surgical Aortic Valve Replacement - An Updated Meta-Analysis of Randomized Controlled Trials.Cardiovasc Revasc Med. 2020 Apr;21(4):441-452. doi: 10.1016/j.carrev.2019.08.003. Epub 2019 Aug 12. Cardiovasc Revasc Med. 2020. PMID: 31678116
-
Transcatheter versus surgical aortic valve replacement in intermediate-risk patients: Evidence from a meta-analysis.Catheter Cardiovasc Interv. 2017 Sep 1;90(3):504-515. doi: 10.1002/ccd.27041. Epub 2017 Apr 11. Catheter Cardiovasc Interv. 2017. PMID: 28398671 Review.
Cited by
-
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial.Eur Heart J. 2024 Apr 1;45(13):1116-1124. doi: 10.1093/eurheartj/ehae043. Eur Heart J. 2024. PMID: 38321820 Free PMC article. Clinical Trial.
-
Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis.J Cardiothorac Surg. 2020 Jun 29;15(1):157. doi: 10.1186/s13019-020-01203-1. J Cardiothorac Surg. 2020. PMID: 32600369 Free PMC article.
-
Advances in transcatheter aortic valve replacement.J Geriatr Cardiol. 2019 Sep;16(9):724-732. doi: 10.11909/j.issn.1671-5411.2019.09.002. J Geriatr Cardiol. 2019. PMID: 31645860 Free PMC article. Review.
-
Transcatheter Aortic Valve Replacement in Large Annuli Valves With the Supra-Annular, Self-Expandable Evolut Platform in a Real-World Registry.Circ Cardiovasc Interv. 2023 Mar;16(3):e012623. doi: 10.1161/CIRCINTERVENTIONS.122.012623. Epub 2023 Mar 21. Circ Cardiovasc Interv. 2023. PMID: 36943929 Free PMC article.
-
A Review of the Cost Effectiveness of Transcatheter Aortic Valve Replacement (TAVR) Versus Surgical Aortic Valve Replacement (SAVR).Cureus. 2023 Oct 5;15(10):e46535. doi: 10.7759/cureus.46535. eCollection 2023 Oct. Cureus. 2023. PMID: 37927639 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical